回盛生物
(300871)
| 流通市值：43.26亿 | | | 总市值：43.26亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 864,930,090.25 | 458,217,021.87 | 1,681,248,059.49 | 1,259,534,029.86 |
| 营业收入 | 864,930,090.25 | 458,217,021.87 | 1,681,248,059.49 | 1,259,534,029.86 |
| 二、营业总成本 | 702,717,089.76 | 363,647,395.52 | 1,414,179,951.34 | 1,066,684,555.95 |
| 营业成本 | 555,966,575.42 | 295,494,556.18 | 1,160,262,921.56 | 889,644,031.92 |
| 税金及附加 | 8,633,302.8 | 4,622,206.15 | 10,794,710.99 | 8,182,498.84 |
| 销售费用 | 46,853,229.47 | 22,433,637.16 | 83,921,698.46 | 57,449,799.13 |
| 管理费用 | 35,648,923.08 | 17,889,527.11 | 66,465,449.35 | 46,896,354.18 |
| 研发费用 | 53,775,263.96 | 24,402,366.07 | 79,818,086.34 | 54,023,597.12 |
| 财务费用 | 1,839,795.03 | -1,194,897.15 | 12,917,084.64 | 10,488,274.76 |
| 其中:利息费用 | 75,192 | -1,826,549.58 | 13,615,262.68 | 12,132,506.09 |
| 其中:利息收入 | 977,127.76 | 267,287.44 | 2,035,955.79 | 1,603,924.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,481,812.46 | -8,757,938.32 | 1,204,788.1 | 6,374,881.21 |
| 加:投资收益 | 605,161.33 | 1,284,599.53 | 8,886,087.59 | 5,013,846.27 |
| 资产处置收益 | 51,323,428.8 | - | - | - |
| 资产减值损失(新) | -2,490,683.09 | -1,598,388.78 | -2,227,243.12 | -1,924,010.31 |
| 信用减值损失(新) | -4,235,692.2 | -2,076,232.94 | -6,722,662.98 | -4,233,788.48 |
| 其他收益 | 21,678,911.26 | 3,910,833.21 | 22,265,481.51 | 18,483,680.26 |
| 四、营业利润 | 233,575,939.05 | 87,332,499.05 | 290,474,559.25 | 216,564,082.86 |
| 加:营业外收入 | 89,882.49 | 53,120.26 | 1,145,696.67 | 389,412.29 |
| 减:营业外支出 | 63,515.78 | 45,809.48 | 2,966,058.61 | 2,365,704.44 |
| 五、利润总额 | 233,602,305.76 | 87,339,809.83 | 288,654,197.31 | 214,587,790.71 |
| 减:所得税费用 | 27,160,234.97 | 9,095,307.5 | 35,165,546.6 | 26,103,064.87 |
| 六、净利润 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 | 188,484,725.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 | 188,484,725.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 205,760,223.49 | 77,674,741.18 | 253,155,975.55 | 187,906,284.66 |
| 少数股东损益 | 681,847.3 | 569,761.15 | 332,675.16 | 578,441.18 |
| 扣除非经常损益后的净利润 | 142,261,061.29 | 78,693,990.43 | 230,559,616.54 | 165,847,022.16 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.02 | 0.38 | 1.33 | 1.01 |
| (二)稀释每股收益 | 1.02 | 0.38 | 1.29 | 1.01 |
| 八、其他综合收益 | - | - | - | -2,310,824.87 |
| 归属于母公司股东的其他综合收益 | - | - | - | -2,310,824.87 |
| 九、综合收益总额 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 | 186,173,900.97 |
| 归属于母公司股东的综合收益总额 | 205,760,223.49 | 77,674,741.18 | 253,155,975.55 | 185,595,459.79 |
| 归属于少数股东的综合收益总额 | 681,847.3 | 569,761.15 | 332,675.16 | 578,441.18 |
| 公告日期 | 2026-08-15 | 2026-04-28 | 2026-04-17 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |